Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Standard BioTools ( (LAB) ) has issued an update.
Standard BioTools announced preliminary, unaudited revenue results for the fourth quarter and full year 2024, reporting approximately $46.5 million for the quarter and $174 million for the year. Despite industry-wide challenges, the company reached the upper end of its revised forecast and has been implementing the Standard BioTools Business Systems to reduce operating expenses. The company plans to further enhance efficiencies and shift towards high-margin markets in 2025, aiming to deliver long-term value to shareholders and customers.
More about Standard BioTools
Standard BioTools Inc. is a leading solutions provider in the biomedical industry, offering standardized next-generation technologies such as SomaScan, mass cytometry, and microfluidics. These tools assist researchers in enhancing the development of medicines and improving patient outcomes. The company collaborates with various academic, government, pharmaceutical, biotechnology, and clinical laboratories worldwide, focusing on areas like oncology, immunology, and immunotherapy.
YTD Price Performance: -6.86%
Average Trading Volume: 1,811,409
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $606.8M
See more data about LAB stock on TipRanks’ Stock Analysis page.
